PK/PD study of meropenem in patients with abdominal septic shock - Recommended dosing regimen for prevention of CRO

Study on optimal antimicrobial treatment of meropenem in septic shock patients under the guidance of pharmacokinetic/pharmacodynamic theory

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063065

Enrollment

Unknown

Registered

2022-08-30

Start date

2022-08-20

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock in the abdomen

Interventions

Group 1:Patients were given meropenem 1.0 g/30min static point infusion model within 1 hour after admission to ICU (50 ml normal saline + meropenem 1.0 g).

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Patients with abdominal sepsis due to gastrointestinal perforation (Sepsis 3.0 diagnostic criteria for sepsis or septic shock released by the American Society of Critical Care Medicine and the European Society of Critical Care Medicine).

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating patients; 2. Patients with acute and chronic renal insufficiency; 3. Patients using probenecid, glyceryl valproate and sodium valproate; 4. Patients who are allergic to this product or other carbapenem antibiotics; 5. Patients who have used meropenem 7 days before admission to the ICU; 6. Patients who are in accordance with our anti-infection program due to various reasons; 7. Patients who have not signed the informed consent.

Design outcomes

Primary

Measure	Time frame
Meropenem plasma concentration;	—

Countries

China

Contacts

Public ContactDong Zhang

Jilin University

zhangdong@jlu.edu.cn+86 15948350236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026